Cancer Chemopreventive and Anticancer Evaluation of Extracts and Fractions from Marine Macro- and Microorganisms Collected from Twilight Zone Waters around Guam [1]
Free accessResearch articleFirst published online December, 2009
Cancer Chemopreventive and Anticancer Evaluation of Extracts and Fractions from Marine Macro- and Microorganisms Collected from Twilight Zone Waters around Guam [1]
The cancer chemopreventive and cytotoxic properties of 50 extracts derived from Twilight Zone (50–150 m) sponges, gorgonians and associated bacteria, together with 15 extracts from shallow water hard corals, as well as 16 fractions derived from the methanol solubles of the Twilight Zone sponge Suberea sp, were assessed in a series of bioassays. These assays included: Induction of quinone reductase (QR), inhibition of TNF-α activated nuclear factor kappa B (NFκB), inhibition of aromatase, interaction with retinoid X receptor (RXR), inhibition of nitric oxide (NO) synthase, inhibition 2,2-diphenyl-1-picrylhydrazyl radical scavenging (DPPH), and inhibition of HL-60 and MCF-7 cell proliferation. The results of these assays showed that at least 10 extracts and five fractions inhibited NFκB by greater than 60%, two extracts and two fractions inhibited DPPH by more than 50%, nine extracts and two fractions affected the survival of HL-60 cells, no extracts or fractions affected RXR, three extracts and six fractions affected quinone reductase (QR), three extracts and 12 fractions significantly inhibited aromatase, four extracts and five fractions inhibited nitric oxide synthase, and one extract and no fractions inhibited the growth of MCF-7 cells by more than 95%. These data revealed the tested samples to have many and varied activities, making them, as shown with the extract of the Suberea species, useful starting points for further fractionation and purification. Moreover, the large number of samples demonstrating activity in only one or sometimes two assays accentuates the potential of the Twilight Zone, as a largely unexplored habitat, for the discovery of selectively bioactive compounds. The overall high hit rate in many of the employed assays is considered to be a significant finding in terms of “normal” hit rates associated with similar samples from shallower depths.
SchuppP, Kohlert-SchuppC, PezzutoJM, KondratyukTP, ParkE-J, LauraMarler L, WrightAD. (2009) Chemoprotective and anticancer screening of extracts from marine macro- and micro-organisms sampled from waters around Guam. Presented in part at the 50thAnnual Meeting of the American Society of Pharmacology Meeting, June 27 – July 1, Honolulu, Hawaii, Congress Abstract, P-416.
2.
MarinLit, Version2008. A marine literature database produced and maintained by the Department of Chemistry, University of Canterbury, New Zealand.
3.
McClintockJB, BakerBJ (2001) Marine Chemical Ecology.CRC Press, Boca Raton, USA.
FaulknerDJ. (2000) Marine pharmacology. Antonie Van Leeuwenhoek, 77, 135–145.
6.
WrightAD, McCluskeyA, MacgregorK, GuentherJ. (2008) Potential ecological role, chemistry and molecular modeling studies of secondary metabolites isolated from the tropical marine sponge Cymbastela hooperi. Planta Medica74, 931.
7.
McKeeTC, CardellinaJH, RiccioR, DauriaMV, IorizziM, MinaleL, MoranRA, GulakowskiRJ, BuckheitRW, SnaderKM, BoydMR. (1994) HIV-inhibitory natural products. 11. Comparative studies of sulfated sterols from marine invertebrates. Journal of Medicinal Chemistry, 37, 793–797.
8.
CoulsonFR, O'DonnellSR. (2000) The effects of contignasterol (IZP-94,005) on allergen-induced plasma protein exudation in the tracheobronchial airways of sensitized guinea-pigs in vivo. Inflammation Research49, 123–127.
9.
KikuchiA, NiedaM, SchmidtC, KoezukaY, IshiharaS, IshikawaY, TadokoroK, DurrantS, BoydA, JujiT, NicolA. (2001) In vitro antitumour activity of α-galactosylceramidestimulated human invariant Vα24+NKT cells against melanoma. British Journal of Cancer, 85, 741–746.
10.
FaulknerDJ, HarperMK, HaygoodMG, SalomonCE, SchmidtEW. (2000) Symbiotic bacteria in sponges: sources of bioactive substances. In: Drugs from the Sea. FusetaniN. (Ed.). Karger, Basel. 107–119.
11.
MunroMHG, BluntJW, LakeRJ, LitaudonM, BattershillCN, PageMJ. (1994) From seabed to sickbed: What are the prospects? In: Sponges in time and space. Van SoestRWM, van KempenTMG, BraekmanJC. (Eds). AA Balkema, Rotterdam, Netherlands, 473–484.
12.
PomponiSA, WilloughbyR (1994) Sponge cell culture for production of bioactive metabolites. In: Sponges in time and space. Van SoestRWM, van KempenTMG, BraekmanJC. (Eds.). AA Balkema, Rotterdam, Netherlands. 395–400.
13.
OsingaR, TramperJ, WijffelsRH. (1998) Cultivation of marine sponges for metabolite production: applications for biotechnology?Trends in Biotechnology, 16, 130–134.
14.
BlackhallFH, RansonM, RadfordJA, HancockBW, SoukopM, McGownAT, RobbinsA, HalbertG, JaysonGC. (2001) A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. British Journal of Cancer, 84, 465–469.
15.
LopanikN, LindquistN, TargettN. (2004) Potent cytotoxins produced by a microbial symbiont protect host larvae from predation. Oecologia, 139, 131–139.
16.
HaygoodMG, DavidsonSK. (1997) Small-subunit rRNA genes and in-situ hybridization with oligonucleotides specific for bacterial symbionts in larvae of the bryozoan Bugula neritina and proposal of “Candidatus Endobugula sertula”. Applied Environmental Microbiology, 63, 4612–4616.
17.
ProkschP, EdradaRA, EbelR. (2002) Drugs from the seas: Current status and microbiological implications. Applied Microbiology and Biotechnology, 59, 125–134.
18.
ThomsC, SchuppPJ. (2005) Biotechnological potential of marine sponges and their associated bacteria as producers of new pharmaceuticals (Part II). Journal of International Biotechnology Law, 2, 257–264.
19.
ThomsC, SchuppPJ. (2005) Biotechnological potential of marine sponges and their associated bacteria as producers of new pharmaceuticals (Part I). Journal of International Biotechnology Law, 2, 217–220.
20.
VaceletJ. (1975) Étude en microscopie électronique de l'association entre bactéries et spongiaires du genre Verongia (Dictyoceratida). Journal of Microscopy and Biology of the Cell, 23, 271–288.
21.
BewleyCA, FaulknerDJ. (1998) Lithistid sponges: Star performers or hosts to the stars?Angewandte Chemie International Edition, 37, 2162–2178.
22.
SalomonCE, DeerinckT, EllismanMH, FaulknerDJ. (2001) The cellular localization of dercitamide in the Palauan sponge Oceanapia sagittaria. Marine Biology139, 313–319.
23.
BewleyCA, HollandND, FaulknerDJ. (1996) Two classes of metabolites from Theonella swinhoei are localized in distinct populations of bacterial symbionts. Experientia, 52, 716–722.
24.
SchmidtEW, ObraztsovaAY, DavidsonSK, FaulknerDJ, HaygoodMG. (2000) Identification of the antifungal peptide-containing symbiont of the marine sponge T. swinhoei as a novel deltaproteobacterium, “Candidatus Entotheonella palauensis”. Marine Biology, 136, 969–977.
25.
BurjaAM, HillRT. (2001) Microbial symbionts of the Australian Great Barrier Reef sponge, Candidaspongia flabellata. Hydrobiologia461, 41–47.
Santiago-VazquezLZ, BrueckT, BrueckWM, Duque-AlarconAP, McCarthyPJ, KerrRG. (2007) The diversity of the bacterial communities associated with the azooxanthellate hexacoral Cirrhipathes lutkeni. The ISME Journal1, 654–659.
30.
LairdSA, ten KateK. (1999) In: The Commercial Use of Biodiversity. Access to Genetic Resources and Benefit-Sharing, ten KateK, LairdSA. (Eds.). Earthscan Publications, London. 34–77.
31.
CraggGM, NewmanDJ. (2005) International collaboration in drug discovery and development from natural sources. Pure and Applied Chemistry, 77, 1923–1942.
32.
CraggGM, NewmanDJ, YangSS. (2006) Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. Journal of Natural Products, 69, 488–498.
33.
WuK, KimHT, RodriquezJL, HilsenbeckSG, MohsinSK, XuXC, LamphWW, KuhnJG, GreenJE, BrownPH. (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiology Biomarkers and Prevention, 11, 467–474.
34.
KangY-H, PezzutoJM. (2004) Induction of quinone reductase as a primary screen for natural product anticarcinogens. In: Quinones and Quinone Enzymes (A Volume of Methods in Enzymology), SiesH, PackerL (Eds.), Elsevier Science, San Diego, California, USA. 380–414.
35.
LubetRA, SteeleVE, CaseboltTL, EtoI, KelloffGJ, GrubbsCJ. (1994) Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostendione in the methylnitrosourea (MNU)-induced mammary tumor model in Spague-Dawley rats. Carcinogenesis, 15, 2775–2780.
36.
GubsonDE, SteeleRE, ChauRY. (1995) Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. British Journal of Cancer, 72, 72–75.
37.
CrowellJA, SteeleVE, SigmanCC, FayJR. (2003) Is inducible nitric oxide synthase a target for chemoprevention?Molecular Cancer Therapy, 2, 815–823.
38.
PezzutoJM, KosmederJWII, ParkEJ, LeeSK, CuendetM, GillsJ, BhatK, GrubjesicS, ParkH-S, Mata-GreenwoodE, TanYM, YuR, LantvitDD, KinghornAD. (2005) Characterization of Natural Product Chemopreventive Agents. In: Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, KelloffGJ, HawkET, SigmanCC., (Eds.), Humana Press Inc., Totowa, New Jersey, USA.3–37.
39.
Francy-GuilfordJ, PezzutoJM. (2008) Mechanisms of cancer chemopreventive agents: A perspective. Planta Medica, 74, 1644–1650.
40.
HomhualS, BunyapraphatsaraN, KondratyukTP, HerunsaleeA, ChaukulW, PezzutoJM, FongHS, ZhangHJ. (2006) Bioactive dammarane triterpenes from the mangrove plant Bruguiera gymnorrhiza. Journal of Natural Products69, 421–424.
41.
MagalhãesLM, SegundoMA, ReisS, LimaJL. (2008) Methodological aspects about in vitro evaluation of antioxidant properties. Analytica Chimica Acta, 613, 1–19.
42.
LeeSK, MbwamboZH, ChungH, LuyengiL, GamezEJ, MehtaRG, KinghornAD, PezzutoJM.(1998) Evaluation of the antioxidant potential of natural products. Combinatorial Chemistry and High Throughput Screening, 1, 35–46.
43.
TanakaT, SuhKS, LoAM, De LucaLM. (2007) p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer. Journal of Biological Chemistry, 282, 29987–29997.
44.
SuBN, GuJQ, KangYH, ParkEJ, PezzutoJM, KinghornAD. (2004) Induction of the phase II enzyme, quinone reductase, by withanolides and norwithanolides from Solanaceous species. Mini-Reviews in Organic Chemistry, 1, 115–123.
45.
MaitiA, CuendetM, CroyVL, EndringerDC, PezzutoJM, CushmanM. (2007) Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. Journal of Medicinal Chemistry, 50, 2799–2806.
46.
KimY, MinHY, ParkHJ, LeeEJ, ParkEJ, HwangHJ, JinC, LeeYS, LeeSK. (2004) Suppressive effects of nitric oxide production and inducible nitric oxide synthase (iNOS) gene expression by Calystegia soldanella methanol extract on lipopolysaccharide-activated RAW 264.7 cells. European Journal of Cancer Prevention, 13, 419–424.
47.
LeeEJ, MinHY, ChungHJ, ParkEJ, ShinDH, JeongLS, LeeSK. (2005) A novel adenosine analog, thio-Cl-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochemistry and Pharmacology, 70, 918–924.
48.
YouM, WickramaratneDB, SilvaGL, ChaiH, ChagwederaTE, FarnsworthNR, CordellGA, KinghornAD, PezzutoJM. (1995) Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. Journal of Natural Products, 58, 598–604.
